Brain

Vesalio Announces Clinical Study Initiative for the Recently Launched pVasc Thrombectomy System and Planned Attendance at TCT, VIVA, and VEITH Meetings

Vesalio Introduces pVasc™ U.S. clinical study initiative to capture real-world data and optimize results for patients suffering from peripheral vascular disease …

1 year ago

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.

Name Change Reflects Extensive Scientific and Corporate Brand Equity Previously Established under Grace Therapeutics Grace Therapeutics will begin trading on…

1 year ago

CarnoSyn® Brands Announces New U.S. Distribution Agreement With B&D Nutritional Ingredients

CARLSBAD, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- CarnoSyn® Brands and parent company Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII),…

1 year ago

Synergy CHC Corp. Announces Closing of Initial Public Offering

WESTBROOK, Maine, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy”), a provider of consumer health care,…

1 year ago

INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination

Data from Animal Model Study Demonstrate XPro™ converts microglia from a demyelinating cell to a remyelinating cell Multi-year study published…

1 year ago

Ayana Bio to Showcase Plant Cell Advantage™ Health & Wellness Ingredients at SupplySide West 2024

Ayana Bio's NeuroAdvantage and ImmunAdvantage prototypes will be available at SupplySide West booth #7071. BOSTON, Oct. 24, 2024 /PRNewswire/ --…

1 year ago

Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study

DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups KELOWNA, BC / ACCESSWIRE / October 24, 2024…

1 year ago

BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024

- Continued, progressive improvement in motor function and achievement of motor milestones at 12-months post-treatment represents an important and statistically…

1 year ago

AlzeCure to Present at the International Partnering Conference Bioscience 2024 on November 7

STOCKHOLM, SE / ACCESSWIRE / October 24, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a…

1 year ago

MEDTEQ+ and AGE-WELL announce 16 envisAGE collaborative projects to enhance older adults’ quality of life with Canadian innovations

EDMONTON, AB, Oct. 23, 2024 /CNW/ - MEDTEQ+ and AGE-WELL proudly announce the first 16 collaborative projects resulting from an unprecedented national…

1 year ago